MedTrace Logo

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

NCT03853993 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2380

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged over 3 years

Conditions

Interventions

BIOLOGICAL

Quadrivalent influenza vaccine

Received single dose QIV (15µg/0.5ml)

BIOLOGICAL

Trivalent influenza vaccine (contains B/Victoria strain)

Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)

BIOLOGICAL

Trivalent influenza vaccine (contains B/Yamagata strain)

Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yuemei Hu, Bachelor · Jiangsu Province Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-23
Primary Completion
2018-08-17
Completion
2018-10-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03853993 on ClinicalTrials.gov